CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Strong product pipeline
4.1.2. Rising prevalence of neurological disorders and increasing ageing population
4.1.3. Increasing awareness and approvals for new neuromodulation devices
4.1.4. Government investments and funds
4.1.5. Expanded target applications and new indications
4.2. Market Restraints & Challenges
4.2.1. Reimbursement issues
4.2.2. Lack of skilled professionals
4.2.3. Stringent approval policies
4.3. Market Opportunities
4.3.1. Expansion in emerging economies
CHAPTER 5. GLOBAL NEUROMODULATION MARKET– BY TECHNOLOGY
5.1. Internal Neuromodulation
5.1.1. Spinal Cord Stimulation
5.1.2. Deep Brain Stimulation
5.1.3. Vagus Nerve Stimulation
5.1.4. Sacral Nerve Stimulation
5.1.5. Gastric Electrical Stimulation
5.2. External Neuromodulation
5.2.1. Transcutaneous Electrical Nerve Stimulation
5.2.2. Transcranial Magnetic Stimulation
5.2.3. Respiratory Electrical Stimulation
CHAPTER 6. GLOBAL NEUROMODULATION MARKET – BY BIOMATERIAL
6.1. Ceramic
6.2. Metallic
6.3. Polymeric
CHAPTER 7. GLOBAL NEUROMODULATION MARKET – BY APPLICATION
7.1. Spinal Cord Stimulation
7.1.1. Chronic Pain
7.1.2. Failed Back Syndrome
7.1.3. Ischemia
7.2. Deep Brain Stimulation
7.2.1. Parkinson’s Disease
7.2.2. Tremor
7.2.3. Depression
7.2.4. Others
7.3. Vagus Nerve Stimulation
7.3.1. Epilepsy
7.3.2. Others
7.4. Sacral Nerve Stimulation
7.4.1. Urine Incontinence
7.4.2. Fecal Incontinence
7.5. Gastric Electrical Stimulation
7.5.1. Gastroparesis
7.5.2. Obesity
7.6. Transcutaneous Electrical Nerve Stimulation
7.6.1. Treatment-Resistant Depression
7.6.2. Others
7.7. Spinal Cord Injury
7.8. Others
CHAPTER 8. GLOBAL NEUROMODULATION MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL NEUROMODULATION MARKET - COMPANY PROFILES
9.1. Medtronic PLC
9.2. Boston Scientific Corporation
9.3. Accellent
9.4. NeuroPace, Inc.
9.5. Nervo Corporation
9.6. Synapse Biomedical, Inc.
9.7. DynaMD
9.8. Biocontrol Medical
9.9. NeuroSigma, Inc.
9.10. Soterix Medical, Inc.
9.11. St. Jude Medical, Inc.
9.12. Cyberonics, Inc.
9.13. Neuronetics, Inc.
9.14. LivaNova PLC
9.15. EnteroMedics, Inc.
CHAPTER 10. GLOBAL NEUROMODULATION MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
